NYSE - Delayed Quote USD

Eli Lilly and Company (LLY)

Compare
934.14 -5.64 (-0.60%)
At close: July 11 at 4:00 PM EDT
933.00 -1.14 (-0.12%)
After hours: July 11 at 7:59 PM EDT
Loading Chart for LLY
DELL
  • Previous Close 939.78
  • Open 934.09
  • Bid 933.85 x 1100
  • Ask 934.95 x 1100
  • Day's Range 918.62 - 942.88
  • 52 Week Range 434.34 - 945.69
  • Volume 2,853,075
  • Avg. Volume 2,734,601
  • Market Cap (intraday) 841.104B
  • Beta (5Y Monthly) 0.41
  • PE Ratio (TTM) 137.98
  • EPS (TTM) 6.77
  • Earnings Date Aug 8, 2024
  • Forward Dividend & Yield 5.20 (0.55%)
  • Ex-Dividend Date Aug 15, 2024
  • 1y Target Est 882.68

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

www.lilly.com

43,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: LLY

View More

Related Videos: LLY

Performance Overview: LLY

Trailing total returns as of 7/11/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

LLY
60.81%
S&P 500
17.08%

1-Year Return

LLY
107.68%
S&P 500
26.65%

3-Year Return

LLY
310.99%
S&P 500
27.81%

5-Year Return

LLY
777.46%
S&P 500
86.58%

Compare To: LLY

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: LLY

View More

Valuation Measures

Annual
As of 7/10/2024
  • Market Cap

    846.18B

  • Enterprise Value

    869.81B

  • Trailing P/E

    138.41

  • Forward P/E

    68.49

  • PEG Ratio (5yr expected)

    1.52

  • Price/Sales (ttm)

    23.63

  • Price/Book (mrq)

    66.05

  • Enterprise Value/Revenue

    24.21

  • Enterprise Value/EBITDA

    89.77

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.08%

  • Return on Assets (ttm)

    12.60%

  • Return on Equity (ttm)

    50.75%

  • Revenue (ttm)

    35.93B

  • Net Income Avi to Common (ttm)

    6.14B

  • Diluted EPS (ttm)

    6.77

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.65B

  • Total Debt/Equity (mrq)

    204.28%

  • Levered Free Cash Flow (ttm)

    -1.23B

Research Analysis: LLY

View More

Analyst Price Targets

600.00 Low
882.68 Average
934.14 Current
1,041.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: LLY

Research Reports: LLY

View More
  • Daily – Vickers Top Buyers & Sellers for 07/10/2024

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

     
  • Daily – Vickers Top Buyers & Sellers for 07/09/2024

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

     
  • Eli Lilly: Announced Morphic Acquisition Yields Potential New Blockbuster Inflammatory Bowel Drug

    Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

    Rating
    Price Target
     
  • Daily – Vickers Top Buyers & Sellers for 07/05/2024

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

     

People Also Watch